ALEXION PHARMACEUTICALS INC.

Company Overview

Alexion Pharmaceuticals Inc. (Alexion) is a global biopharmaceutical company focused on serving patients and families that have been affected by rare diseases. Alexion is focused on the discovery, development and commercialization of life-changing therapies. Alexion has 25 years of leadership in rare diseases. The company delivers transformative medicines to people with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis Optica spectrum disorder (NMOSD), generalized Myasthenia Gravis (gMG), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D).

In July 2021, AstraZeneca completed its acquisition of Alexion Pharmaceuticals Inc. Through this acquisition, AstraZeneca enters the medicines for rare diseases market. As of July 2021, Alexion Pharmaceuticals operates as a subsidiary of AstraZeneca.Alexion has five innovative medicines approved for the treatment of seven rare diseases and devastating conditions: Andexxa (coagulation factor Xa (recombinant)), Kanuma (sebelipase alpha), Soliris (eculizumab), Strensiq (asfotase alpha) and Ultomiris (ravulizumab). The business development team is currently evaluating opportunities with an exclusive focus on developing life-changing therapies for patients with rare diseases that lack effective treatment options in core areas of focus, including hematology, nephrology, neurology, metabolic and cardiology. Alexion is also seeking partnerships to maximize the potential of internal research efforts through select opportunities. The company reported a net revenue of $6.07 billion in 2020.

Company's Business Segments

• Biotechnology Research : This segment of the company includes finding Medicines for Rare Diseases in Biotechnology, Biopharmaceutical, Complement Inhibition, Metabolic Disorders, Neurology.